Rekombinanter ZIKV E Antikörper

Produktnummer ABIN6253501

Dieses Anti-ZIKV E-Antikörper ist ein Human Monoklonal-Antikörper zur Detektion von ZIKV E in Func. Geeignet für Zika Virus (ZIKV).

Kurzübersicht für Rekombinanter ZIKV E Antikörper (ABIN6253501)

Target: ZIKV E (Zika Virus Envelope (ZIKV E))

Antikörpertyp: Recombinant Antibody

Reaktivität: Zika Virus (ZIKV)

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser ZIKV E Antikörper ist unkonjugiert

Applikation: Functional Studies (Func)

Klon: ZKA64

Produktdetails anti-ZIKV E Antikörper

Verwendungszweck: anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)

Produktmerkmale: Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.

Reinheit: >95 % (SDS-PAGE)

Endotoxin-Niveau: <0.001EU/μg

Immunogen: Zika Virus

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: Liquid. In PBS.

Konservierungsmittel: Without preservative

Handhabung: Avoid freeze/thaw cycles.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.

Details zu ZIKV E

Target: ZIKV E (Zika Virus Envelope (ZIKV E))

Andere Bezeichnung: Zika Virus Envelope Protein

Substanzklasse: Viral Protein

Hintergrund:

Alternate Names/Synonyms: ZIKV E Protein

Product Description: The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.